Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study

Fig. 1

Level of biomarker suppression in early responders (solid line) and non-responders (dotted line) in response to 8 mg/kg tocilizumab (TCZ). Levels of (a) matrix metalloproteinase (MMP)-mediated type I collagen fragments (C1M), (b) MMP-mediated type II collagen degradation fragments (C2M), (c) MMP-mediated type III collagen degradation fragments (C3M), and (d) total MMP-mediated C-reactive protein degradation fragments (CRPM). Data are percentage change from baseline and mean ± standard error. Absolute values can be found in Additional file 1: Table S1

Back to article page